Schmid Andreas, Roderfeld Martin, Karrasch Thomas, Roeb Elke, Schäffler Andreas
Department of Internal Medicine III, Justus Liebig University, 35392 Giessen, Germany.
Department of Gastroenterology, Justus Liebig University, Klinikstr. 33, 35392 Giessen, Germany.
Biomedicines. 2023 Dec 22;12(1):33. doi: 10.3390/biomedicines12010033.
The pleiotropic chemokine chemerin is involved in multiple processes in metabolism and inflammation. The present study aimed to elucidate its regulation in morbid obesity and during therapy-induced rapid weight loss. A total of 128 severely obese patients were enrolled, and their basal anthropometric and clinical parameters were assessed. In total, 64 individuals attended a conservative 12-month weight loss program that included a low calorie-formula diet (LCD), and 64 patients underwent bariatric surgery (Roux-en-Y gastric bypass, RYGB). Blood serum was obtained at study baseline and at follow-up visits after 3, 6, and 12 months. Systemic chemerin concentrations, as well as metabolic and immunological parameters, were quantified. During the 12-month period studied, serum chemerin levels decreased significantly with weight loss after bariatric surgery, as well as with conservative low calorie therapy; however, the effects of RYGB were generally stronger. No substantial associations of systemic chemerin concentrations with therapy-induced improvement of type 2 diabetes and with indicators of liver function and fibrosis were observed. We conclude that systemic chemerin levels decrease in obese individuals during weight loss, regardless of the therapeutic strategy. A potential involvement in weight loss-associated improvement of metabolic disorders and liver fibrosis remains to be further investigated.
多效性趋化因子chemerin参与代谢和炎症的多个过程。本研究旨在阐明其在病态肥胖及治疗引起的快速体重减轻过程中的调节作用。共纳入128例重度肥胖患者，并评估了他们的基础人体测量学和临床参数。总共64人参加了一个为期12个月的保守减肥计划，该计划包括低热量配方饮食（LCD），另外64例患者接受了减肥手术（ Roux-en-Y胃旁路术，RYGB）。在研究基线以及3、6和12个月后的随访时采集血清。对全身chemerin浓度以及代谢和免疫参数进行了定量分析。在研究的12个月期间，减肥手术后体重减轻以及保守的低热量治疗后，血清chemerin水平均显著下降；然而，RYGB的效果通常更强。未观察到全身chemerin浓度与治疗引起的2型糖尿病改善以及肝功能和纤维化指标之间存在实质性关联。我们得出结论，无论采用何种治疗策略，肥胖个体在体重减轻期间全身chemerin水平都会下降。其在与体重减轻相关的代谢紊乱和肝纤维化改善中的潜在作用仍有待进一步研究。
